Skip to main content
Premium Trial:

Request an Annual Quote

Atum, Horizon Discovery Sign Cross-Licensing Deal for Cell Line Production Tech

NEW YORK (GenomeWeb) – Atum and Horizon Discovery announced today that they have signed a cross-licensing agreement for their respective cell line production technologies.

Under the terms of the deal, Atum — formerly DNA2.0 — has been given a license to Horizon's CHO Source biomanufacturing platform, including the glutamine synthetase (GS) knockout CHO K1 line, which it will combine with its own Leap-In transposase technology as a cell line development service. Horizon, meanwhile, has been given an exclusive license to a vector suite developed by Atum for the CHO Source platform. Horizon customers will also be offered a no-fee evaluation license for the Leap-In system.

Additional terms were not disclosed.

"Horizon's GS line and Atum's vectors and transposase technology are a very powerful combination for production of stable cell lines," Atum Cofounder and CEO Jeremy Minshull said in a statement. "This technology is suited not just for regular antibodies, but for the next wave of biologics including two, three, and four-chain bispecifics, and require only small numbers of clones to be screened to reach commercial titers."

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.